Completed NCT01010776
This study is completed in Brazil. It is testing Flexible-Dose of Paliperidone Extended Release (ER) for schizophrenia.
Multiple locations, including Belo Horizonte Schizophrenia Drug i A study involving a medication or substance. From 18 Years to 60 Years
Countries Brazil
Sponsor Janssen-Cilag Farmaceutica Ltda.
Condition Schizophrenia Completed NCT00890292
This study is completed. It is testing Pharmacokinetics, Safety and Tolerability After a Single Dose Administration of JNJ-31001074 for ADHD.
Location not clearly listed ADHD Drug From 12 Years to 17 Years
Countries
Sponsor Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Condition ADHD Completed NCT00890240
This study is completed. It is testing Pharmacokinetics, Safety and Tolerability After a Single Dose Administration of of JNJ-31001074 for ADHD.
Location not clearly listed ADHD Drug From 6 Years to 11 Years
Countries
Sponsor Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Condition ADHD Enrolling By Invitation NCT05814653
This study is enrolling by invitation in the United States. It is testing primary Care Treatment for Eating disorders.
In Rochester Eating disorders Behavioral From 7 Years to 18 Years
Countries United States
Sponsor Mayo Clinic
Condition Eating disorders Completed NCT05686239
This study is completed in the United States, in Bulgaria, in Czechia, .... It is testing RL-007 for schizophrenia.
Multiple locations, including Culver City Schizophrenia Behavioral From 18 Years to 55 Years
Countries United States, Bulgaria, Czechia, ...
Sponsor Recognify Life Sciences
Condition Schizophrenia Completed NCT02942017
This study is completed in the United States. It is testing Safety and Efficacy of SAGE-547 for depression.
Multiple locations, including Chandler Depression Drug From 18 Years to 45 Years
Countries United States
Sponsor Supernus Pharmaceuticals, Inc.
Condition Depression Completed NCT05443724
This study is completed in the United States, in Bulgaria, in Hungary, .... It is testing CVL-231 (Emraclidine) for schizophrenia.
Multiple locations, including Phoenix Schizophrenia Drug From 18 Years to 65 Years
Countries United States, Bulgaria, Hungary, ...
Sponsor AbbVie
Condition Schizophrenia Completed NCT03692910
This study is completed in the United States. It is testing SAGE-217 for depression.
Multiple locations, including Little Rock Bipolarity, Depression Drug From 18 Years to 65 Years
Countries United States
Sponsor Biogen
Condition Bipolarity, Depression Completed NCT02614547
This study is completed in the United States. It is testing SAGE-547 for depression.
Multiple locations, including Atlanta Depression Drug From 18 Years to 45 Years
Countries United States
Sponsor Supernus Pharmaceuticals, Inc.
Condition Depression Completed NCT07258485
This study is completed in the United States. It is testing Sleep Electroencephalogram (EEG) Features (Brain Activity While Sleeping) for depression.
Multiple locations, including Phoenix Depression Other From 18 Years to 74 Years
Countries United States
Sponsor Janssen Research & Development, LLC
Condition Depression Completed NCT00216528
This study is completed. It is testing symptomatic Remission for schizophrenia.
Location not clearly listed Schizophrenia Drug From 18 Years to 75 Years
Countries
Sponsor Janssen Korea, Ltd., Korea
Condition Schizophrenia Completed NCT03713658
This study is completed in Rwanda. It is testing ability of Conducting a Study of Oral Risperidone Followed by Paliperidone Palmitate for Schizophrenia.
Multiple locations, including Kigali Schizophrenia Drug From 18 Years to 70 Years
Countries Rwanda
Sponsor Janssen Research & Development, LLC
Condition Schizophrenia